Gupta A., Chaturvedi P., Shrivastava S. K., Dubey P.K
Gupta A. *, Chaturvedi P., Shrivastava S. K. and Dubey P.K
Swami Vivekananda College of Pharmacy, Near Toll Naka, Khandwa Road, Indore-452020
Volume - 5,
Issue - 2,
Year - 2012
Diabetes mellitus is a heterogenous group of diseases, characterized by a state of chronic hyperglycemia, resulting from a diversity of etiologies, environmental and genetic, acting jointly. The underlying causes of diabetes are the controls of carbohydrate, fat and protein metabolism. Characterstically diabetes is a long-term disease with variable clinical manifestations and progression, chronic hyperglycemia from whatever cause, leads to a number of complications including cardiovascular such as hypertension, renal, neurological such as anxiety, stress, ocular and other such inter-current infections. Glitazones are used as oral hypoglycemic agents used in diabetes in both combinations with other categories and single because of their targeted site of action these glitazones were used. Glitazones are also known as thaizolidinediones(TZD). Glitazones are agonists for the peroxisome proliferator-activated receptor, PPAR? which regulates the transcription of insulin responsive genes involved in control of glucose production, transport, and utilization. Currently, there are several classes of drugs that are used to manage Type 2 diabetes. However, only the thiazolidinediones (TZDs) have been shown to consistently improve estimates of ß- cell function. By improving insulin sensitivity and potentially preserving ß-cell function, the TZDs are able to provide durable glycemic control. The TZDs also have been found to reduce inflammatory markers, improve vascular function and lipid profiles, and decrease blood pressure in patients with Type 2 diabetes, which may improve long-term cardiovascular outcomes. This reveals that the glitazones used in diabetes because to their targetted site of action it is very useful and effective than other classes of oral hypoglycemics agents.
Cite this article:
Gupta A. , Chaturvedi P., Shrivastava S. K., Dubey P.K. Glitazones for the Treatment of Diabetes Type-2. Asian J. Research Chem. 5(2): February 2012; Page 164-170.